

WETENSCHAPPELIJK INSTITUUT VOLKSGEZONDHEID

INSTITUT SCIENTIFIQUE DE SANTÉ PUBLIQUE



Dr. Anne Van Nerom

Famhp 2017-06-13 Recast-symposium Auditorium Storck (Eurostation II)



Dr. Anne Van Nerom

Coordinator

Belgian Competent Authority for in vitro diagnostic Medical Devices

Scientific Institute for Public Health (WIV-ISP) J. Wytsmanstraat 14 B-1050 Brussels





IVD medical device Regulation Points covered

- * From Directives to Regulation
- * Key points
 - Horizontal aspects
 - IVD specific aspects
- * Clinical performance and clinical evidence
- * Companion diagnostics
- * Timelines
- * End notes



IVD medical device Regulation Points covered

- * From Directives to Regulation
- * Key points
 - Horizontal aspects
 - IVD specific aspects
- * Clinical performance and clinical evidence
- * Companion diagnostics
- * Timelines
- * End notes



EU Medical Device Legislation

three Medical Device Directives

- * Active Implantable MDD
 Directives 90/385/EEC + 2007/47/EC
- *
- Directives 90/385/EEC + 2007/47/EC

Medical Devices MDD

In Vitro Diagnostic MDD - Directive 98/79/EC *Regulation* 2017/745

Regulation 2017/746



From Directives to Regulation (1)

Public consultation 'Recast' 2008

Public consultation 'IVD' 2010

- Questions: input from Ad hoc group
 - \rightarrow analysing the specific needs
 - \rightarrow technical aspects of IVD medical devices

Special MDEG meetings 2012

Recast mirror group

- Ad hoc group from CAMD



From Directives to Regulation (2)

Proposal for an IVD Regulation by Commission 26-09-2012

Amendments adopted by the European Parliament 22-10-2013

Council Working Party reached General Approach 05-10-2015

Consolidated compromise text 15-06-2016



IVD Regulation 2017/746

Regulation (EU) 2017/746 on in vitro diagnostic medical devices

and

repealing Directive 98/79/EC and Commission Decision 2010/227/EU

Official Journal of the European Union, L 117, 5 May 2017

http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2017:117:TOC



IVD medical device Regulation Points covered

- * From Directives to Regulation
- * Key points
 - Horizontal aspects
 - IVD specific aspects
- * Clinical performance and clinical evidence
- * Companion diagnostics
- * Timelines
- * End notes



IVD medical device Regulation Key points

Horizontal aspect:

- alignment IVD and MD Regulation

Specific modifications

- taking account of the specificities of the IVD





IVD medical device Regulation Horizontal aspect

- Notified bodies
- Economic operators
- Post-Market surveillance
- Vigilance
- Market surveillance
- Traceability, UDI and registration
- Summary of safety and performance
- Transparency



IVD medical device Regulation Horizontal aspect - what is new ?

- Notified bodies
- Economic operators
- Post-Market surveillance
- Vigilance
- Market surveillance
- Traceability, UDI and registration
- Summary of safety and performance
- Transparency



IVD medical device Regulation Points covered

- * From Directives to Regulation
- * Key points
 - Horizontal aspects
 - IVD specific aspects
- * Clinical performance and clinical evidence
- * Companion diagnostics
- * Timelines
- * End notes

IVD medical device Regulation IVD: Definition



any medical device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, piece of equipment, software or system, whether used alone or in combination, intended by the manufacturer to be used *in vitro* for the examination of specimens, including blood and tissue donations, derived from the human body

IVD medical device Regulation IVD: Definition (cont.)



... for the purpose of providing information on one or more of the following

- (a) concerning a physiological or pathological process or state;
- (b) concerning congenital physical or mental impairments;
- (c) concerning the **predisposition** to a medical condition or a disease;
- (d) to determine the safety and compatibility with potential recipients;
- (e) to predict treatment response or reactions;
- (f) to define or monitoring therapeutic measures.



IVD medical device Regulation Scope (1)

Scope and definitions

- Enlargement
 - to define or monitor therapeutic measures
- Clarification
 - software ... for the purpose of providing information...
 - predisposition to a medical condition or disease
 - to predict treatment response or reaction
 - service providers

IVD medical device Regulation Scope (2)



'In house' - home brew devices

Manufacture and use within <u>single</u> EU health institution <u>Not</u> manufactured on an <u>industrial scale</u>

- * Annex I is applicable
 - = general safety and performance requirements
- * Class D: document- manufacturing facility,
 - manufacturing process,
 - design and performance data

IVD medical device Regulation Specific for IVD



Provisions taking into account specific risks

- Classification rules
 - * class D > class C > class B > class A
- Conformity assessment
 - * reference laboratory / experts / medicines agency
 - technical documentation examination
- Devices for self-testing
- Devices for near-patient testing
- Companion diagnostics



IVD medical device Regulation Points covered

- * From Directives to Regulation
- * Key points
 - Horizontal aspects
 - IVD specific aspects
- * Clinical performance and clinical evidence
- * Companion diagnostics
- * Timelines
- * End notes

IVD medical device Regulation **Clinical evidence** - Recital (61)



To ensure a high level of safety and performance, demonstration of compliance with the general safety and performance requirements laid down in this Regulation should be based on clinical evidence. It is necessary to clarify the requirements for the demonstration of the clinical evidence, that is

based on data on <u>scientific validity</u>, and the <u>analytical performance</u> and <u>clinical performance</u> of the device.

To allow for a structured and transparent process, generating reliable and robust data, sourcing and assessment of available scientific information and data generated in performance studies should be based on a performance evaluation plan.

.be



IVD medical device Regulation Scientific validity

Definition (38):

"the association of an analyte with a clinical condition or a physiological state"



analyte <> information IVD

IVD medical device Regulation Analytical performance



Annex I, point 9.1 (a)

such as, analytical sensitivity, analytical specificity, trueness (bias), precision (repeatability and reproducibility), accuracy (resulting from trueness and precision), limits of detection and quantitation, measuring range, linearity, cut-off, including determination of appropriate criteria for specimen collection and handling and control of known relevant endogenous and exogenous interference, cross- reactions



correctly detect / measure

IVD medical device Regulation Clinical performance



Annex I, point 9.1 (b)

such as diagnostic sensitivity, diagnostic specificity, positive predictive value, negative predictive value, likelihood ratio, expected values in normal and affected populations



patient <> information IVD

.be

IVD medical device Regulation Clinical evidence - Recital (61)



To ensure a high level of safety and performance, demonstration of compliance with the general safety and performance requirements laid down in this Regulation should be based on clinical evidence. It is necessary to clarify the requirements for the demonstration of the clinical evidence, that is based on data on scientific validity, and the analytical performance and clinical performance of the device. To allow for a structured and transparent process, generating reliable and robust data, sourcing and assessment of available scientific information and data generated in performance studies should be **based on a performance evaluation plan**.

IVD medical device Regulation PMPF - Recital (63)



Post-Market Performance Follow-up PMPF

It is necessary to ensure that the clinical evidence of devices is updated throughout their lifecycle. Such updating entails the **planned monitoring of scientific developments and changes in <u>medical practice</u> by the manufacturer.** Relevant new information should then trigger a reassessment of the clinical evidence of the device thus ensuring safety and performance through a continuous process of performance evaluation.



IVD medical device Regulation PMPF - Recital (63)



Post-Market Performance Follow-up PMPF

It is necessary to ensure that the clinical evidence of devices is updated throughout their lifecycle. Such updating entails the planned monitoring of scientific developments and changes in medical practice by the manufacturer. Relevant new information should then **trigger a reassessment** of the clinical evidence of the device thus ensuring safety and performance through a **continuous process** of performance evaluation.



IVD medical device Regulation Clinical evidence

Performance evaluation

- performance evaluation report
 scientific validity
 analytical performance
 clinical performance
 clinical evidence
- * post market performance follow-up

Chapter VI, Art 56.3 – Annex XIII Performance evaluation – plan –



a defined and methodologically sound procedure to demonstrate

scientific validity analytical performance

clinical performance



analyte \iff information IVD




correctly detect / measure



patient ⇐⇒ information IVD

Clinical evidence ???





.be

Chapter VI, Art 56.3 Clinical evidence



... such as to **scientifically demonstrate**, by reference to the **state of the art in medicine**, that, under normal conditions of use:

- intended clinical benefit(s) will be achieved
- device is **safe**
- general safety and performance requirements of
 Annex I are fulfilled





IVD medical device Regulation Points covered

- * From Directives to Regulation
- * Key points
 - Horizontal aspects
 - IVD specific aspects
- * Clinical performance and clinical evidence
- * Companion diagnostics
- * Timelines
- * End notes

IVD medical device Regulation Companion diagnostics - definition



a device which is essential for the safe and effective use of a corresponding medicinal product to:

- identify, before and/or during treatment, patients who are most likely to benefit from the corresponding medicinal product; or
- identify, before and/or during treatment, patients likely to be at increased risk of serious adverse reactions as a result of treatment with the corresponding medicinal product

IVD medical device Regulation Companion diagnostics - recitals



Additional information

- quantitative or qualitative determination
- specific biomarker(s) in healthy subjects or patients

Not considered companion diagnostics:

 monitoring a treatment with a medicinal product in order to ensure that the concentration of relevant substances in the human body is within the therapeutic window

IVD medical device Regulation wive Companion diagnostics – classification

Annex VIII, Rule 3

Devices are classified as **class C** if they are intended:

(f) to be used as companion diagnostics

If Annex VIII, Rule 1 and 2

- multiple intended purposes
- several classification rules apply
- \rightarrow classified as class D

IVD medical device Regulation

QMS + assessment of the technical documentation or

production quality assurance + type examination

+ opinion medicinal products authority * Member State * EMA

If class D
+ EU reference laboratories +/- experts opinion

IVD medical device Regulation w CDx - performance evaluation studies

Performance studies on left over samples notification

- comply with the general requirements apart aspects studied
- correct design and conduct
- data protection

Other performance studies with CDx *authorisation*

- + ethical considerations
- + performance study plan (design/objectives/hypotheses)
- + performance study report



IVD medical device Regulation Points covered

- * From Directives to Regulation
- * Key points
 - Horizontal aspects
 - IVD specific aspects
- * Clinical performance and clinical evidence
- * Companion diagnostics
- * Timelines
- * End notes



IVD medical device Regulation Timelines



25/05/2017



IVD medical device Regulation Interpretation requested



- * Article 110 Transitional provisions
- * Article 112 Repeal
- * Article 113 Entry into force and date of application



IVD medical device Regulation Points covered

- * From Directives to Regulation
- * Key points
 - Horizontal aspects
 - IVD specific aspects
- * Clinical performance and clinical evidence
- * Companion diagnostics
- * Timelines
- * End notes



IVD medical device Regulation End notes

- clear scope and delineation
- provisions with sufficient level of detail
- defining the responsibilities
- cooperation
- clear classification rules
- intended use performance clinical evidence
- trust in products
- trust in conformity assessment
- transparency

Thank you





Dr. Anne Van Nerom

Coordinator

Belgian Competent Authority IVD

Scientific Institute for Public Health (WIV-ISP)

J. Wytsmanstraat 14

B-1050 Brussels